Comparison of Imipenem prescription model in Imam Khomeini and Taleghani Educational Center of Urmia
Abstract
Introduction: Drug utilization evaluation (DUE) studies are designed to evaluate the rational use of drugs. Our purpose in this study is to evaluate the pattern of Imipenem, a broad-spectrum antibiotic used in different parts of Imam Khomeini and Taleghani Educational Center of Urmia. Method and material: This is a cross-sectional and retrospective study. The study was conducted by reviewing medical records of 200 admitted patients who received Imipenem during March 2016 to 2017. Results: In the study Imipenem was prescribed most frequently for intra-abdominal infection in 71 cases (35.5%), 41cases (20.5%) respiratory infection, 31 cases (15.5%) urinary tract infection, 25 cases (12.5%) skin infection, 15 (7.5%) cases septicemia infection, 7 (3.5%) cases bone and neutropenic infection, endocarditis infection were reported in 3 cases (1.5%). The highest incidence was related to intra-abdominal infections. 61% of Talehgsni hospital patients and 46% of Imam Khomeini hospital patients received Imipenem less than a week. The used dose in all patients was between one to four grams per day and the frequency of use was not correct in 7% of Taleghani hospital patients and 23% of patients in Imam Khomeini hospital. Conclusion: Some AB combination was proved to be inappropriate to the guidline consedering the indication or the microorganism to be covered. It is necessary to take action to improve prescribing habit in order to reduce the unnecessary usage of antibiotic thus enhance rational antibiotic use.Kahan, Frederick M., et al. "Thienamycin: development of imipenem-cilastatin." Journal of Antimicrobial Chemotherapy 12.suppl_D (1983): 1-35.
Mitsuhashi, S. "In-vitro and in-vivo antibacterial activity of imipenem against clinical isolates of bacteria." Journal of Antimicrobial Chemotherapy 12.suppl_D (1983): 53-64.
BARZA, MICHAEL. "Imipenem: first of a new class of beta-lactam antibiotics." Annals of internal medicine 103.4 (1985): 552-560.
Kropp, Helmut, et al. "Antibacterial activity of imipenem: the first thienamycin antibiotic." Reviews of infectious diseases 7.Supplement_3 (1985): S389-S410.
Biron, P., et al. "Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer)." The Journal of antimicrobial chemotherapy 42.4 (1998): 511-518.
Yong, Dongeun, et al. "Imipenem-EDTA disk method for differentiation of metallo-β-lactamase-producing clinical isolates of Pseudomonas spp. and Acinetobacter spp." Journal of clinical microbiology 40.10 (2002): 3798-3801.
Ruiz, J., et al. "Evolution of resistance among clinical isolates of Acinetobacter over a 6-year period." European Journal of Clinical Microbiology and Infectious Diseases 18 (1999): 292-295.
Patzer, Jan A., and Danuta Dzierżanowska. "Increase of imipenem resistance among Pseudomonas aeruginosa isolates from a Polish paediatric hospital (1993–2002)." International journal of antimicrobial agents 29.2 (2007): 153-158.
Quinn, John P., et al. "Resistance to imipenem in Pseudomonas aeruginosa: clinical experience and biochemical mechanisms." Clinical Infectious Diseases 10.4 (1988): 892-898.
Satake, S., H. Yoneyama, and T. Nakae. "Role of OmpD2 and chromosomal β-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa." Journal of Antimicrobial Chemotherapy 28.2 (1991): 199-207.
Senda, Kazuyoshi, et al. "Multifocal outbreaks of metallo-beta-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum beta-lactams, including carbapenems." Antimicrobial agents and chemotherapy 40.2 (1996): 349-353.
Watanabe, M., et al. "Transferable imipenem resistance in Pseudomonas aeruginosa." Antimicrobial agents and chemotherapy 35.1 (1991): 147-151.
Cornaglia, Giuseppe, et al. "Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable metallo-β-lactamase." Clinical infectious diseases 31.5 (2000): 1119-1125.
Lauretti, Laura, et al. "Cloning and characterization of bla VIM, a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate." Antimicrobial agents and chemotherapy 43.7 (1999): 1584-1590.
Woodford, N., et al. "Carbapenemase-producing Pseudomonas aeruginosa in UK." The Lancet 352.9127 (1998): 546-547.
Cardosoa, Olga, et al. "Carbapenem-hydrolysing β-lactamase from clinical isolates of Pseudomonas aeruginosa in Portugal." Journal of Antimicrobial Chemotherapy 44.1 (1999): 135-135.
Tsakris, Athanassios, et al. "Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece." Journal of clinical microbiology 38.3 (2000): 1290-1292.
Clark, Richard B. "Imipenem resistance among Acinetobacter baumannii: association with reduced expression of a 33–36 kDa outer membrane protein." Journal of Antimicrobial Chemotherapy 38.2 (1996): 245-251.
Gehrlein, Max, et al. "Imipenem resistance in Acinetobacter baumanii is due to altered penicillin-binding proteins." Chemotherapy 37.6 (1991): 405-412.
Da Silva, Gabriela J., Rui Leitão, and Luı́sa Peixe. "Emergence of carbapenem-hydrolyzing enzymes in Acinetobacter baumannii clinical isolates." Journal of clinical Microbiology 37.6 (1999): 2109-2110.
Bou, German, et al. "Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of β-lactamases." Journal of Clinical Microbiology 38.9 (2000): 3299-3305.
Takahashi, Ayako, et al. "Detection of carbapenemase-producing Acinetobacter baumannii in a hospital." Journal of clinical microbiology 38.2 (2000): 526-529.
Giraud-Morin, C., and T. Fosse. "A seven-year survey of Klebsiella pneumoniae producing TEM-24 extended-spectrum β-lactamase in Nice University Hospital (1994–2000)." Journal of Hospital Infection 54.1 (2003): 25-31.
Garges, H. P., et al. (2003). Imipenem/cilastatin and Meropenem. NeoReviews, 4(12), e364.
Garges, Harmony P., and Kenneth A. Alexander. "Pharmacology review: newer antibiotics: Imipenem/cilastatin and meropenem." NeoReviews 4.12 (2003): e364-e368.
Hardman, J. G., et al. (2006). The pharmacological basis of Therapeutics, 1150-1151.
Lacy, C. F., et al. (Eds.). (2009). Drug information handbook (19th ed.). Hudson, OH: Lexi-Comp, Inc.
Drugs.com. Imipenem. Retrieved from https://www.drugs.com/pdr/imipenem.html
Nikfar, Shekoufeh, et al. "Monitoring of National Drug Policy (NDP) and its standardized indicators; conformity to decisions of the national drug selecting committee in Iran." BMC International Health and Human Rights 5.1 (2005): 1-10.
Hepler, Charles D., and Linda M. Strand. "Opportunities and responsibilities in pharmaceutical care." American journal of hospital pharmacy 47.3 (1990): 533-543.
American Society of Hospital Pharmacists. (1988). ASHP guidelines on pharmacists' role in drug-use evaluation. American Journal of Hospital Pharmacy, 45, 385-386.
Sakhaiyan, Elnaz, et al. "Drug utilization evaluation of imipenem in patients undergoing bone marrow transplantation." International Journal of Hematology-Oncology and Stem Cell Research (2009): 10-13.
Mousavi, Sarah, et al. "Drug utilization evaluation of imipenem and intravenous ciprofloxacin in a teaching hospital." Iranian journal of pharmaceutical research: IJPR 12.Suppl (2013): 161.
Sakhaiyan, Elnaz, et al. "Drug utilization evaluation of imipenem in patients undergoing bone marrow transplantation." International Journal of Hematology-Oncology and Stem Cell Research (2009): 10-13.
Shiva, Afshin, et al. "Drug utilization evaluation of imipenem in an educational hospital in Mazandaran Province." Pharmaceutical Sciences 20.1 (2014): 12-17.
Kabbara, Wissam K., George T. Nawas, and Wijdan H. Ramadan. "Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital." Infection and drug resistance (2015): 31-38.
Souza, N. P., Antonio Carlos Beisl Noblat, and L. Noblat. "Analysis of the use of imipenem at a University Hospital following the restructuring of an antimicrobial audit system." Brazilian Journal of Infectious Diseases 12 (2008): 494-498.
Afzali, Hasan, and Mansoureh Momen-Heravi. "Evaluation of ciprofloxacin and imipenem resistance among uropathogenic bacterial strains using the disk diffusion and E-test methods in Shahid-Beheshti Hospital in Kashan during 2012-2013." KAUMS Journal (FEYZ) 19.4 (2015): 349-355.
Lim, King-Ting, et al. "Genetic fingerprinting and antimicrobial susceptibility profiles of Pseudomonas aeruginosa hospital isolates in Malaysia." Journal of microbiology, immunology, and infection= Wei mian yu gan ran za zhi 42.3 (2009): 197-209.
Todd, M. W. (1992). Drug use evaluation. In T. R. Brown (Ed.), Handbook of Institutional Pharmacy Practice (3rd ed., pp. 47-51). Bethesda, MD: American Society of Hospital Pharmacists.
Misan, G. M. H., et al. "Drug utilization review in a teaching hospital: experience with vancomycin." European journal of clinical pharmacology 39 (1990): 457-461.
| Files | ||
| Issue | Vol 9 No 4 (2023) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/jppm.v9i4.14608 | |
| Keywords | ||
| Imipenem Drug resista Antibiotics | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
